Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression (BENEFIT)
Status:
Completed
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to learn if Belatacept can provide protection from organ
rejection following kidney transplantation while avoiding some of the toxic effects of
standard immunosuppressive medications such as kidney damage. Effects on kidney function and
patient survival as well as drug safety will also be studied.